Earnings Call Summary | Rapid Micro Biosystems(RPID.US) Q1 2024 Earnings Conference
Earnings Call Summary | Rapid Micro Biosystems(RPID.US) Q1 2024 Earnings Conference
The following is a summary of the Rapid Micro Biosystems, Inc. (RPID) Q1 2024 Earnings Call Transcript:
以下是快速微生物系統公司（RPID）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Rapid Micro Biosystems reported an 11% increase in Q1 total revenue to $5.6 million, surpassing its projected guidance.
Recurring revenue recorded a 15% growth compared to Q1 2023, with consumable sales spiking by 22% YoY.
The company reaffirmed its FY 2024 revenue guidance, forecasting a minimum growth of 20% to $27 million, with at least 20 system placements planned.
The company reported a net loss of $13.3 million for Q1, slightly lower than the $13.9 million net loss in Q1 last year.
It closed the Q1 with $80 million in cash and investments.
Rapid Micro Biosystems報告稱，第一季度總收入增長了11％，達到560萬美元，超過了預期的預期。
與2023年第一季度相比，經常性收入增長了15％，消費品銷售額同比增長了22％。
該公司重申了其2024財年的收入指導，預計最低增長20％至2700萬美元，計劃投放至少20個系統。
該公司報告稱，第一季度淨虧損1,330萬美元，略低於去年第一季度的1,390萬美元淨虧損。
它以8000萬美元的現金和投資結束了第一季度。
Business Progress:
業務進展：
Rapid Micro Biosystems placed three Growth Direct systems in Q1, expanding their current customers' operations.
Increasing customer interest is expected to accelerate system placements in H2 of 2024.
The company plans to improve gross margins and is anticipating positive results by H2 2024.
The Rapid Sterility platform launch is scheduled for mid-2024, with customer interest on the rise.
Through a balance of revenue growth, better margins, and regulated operating expenses, the company has a strategy to reduce cash burn.
Expansion plans include attracting additional global top 20 firms and broadening the customer base to include various segments like sterile injectable manufacturing.
The company showcased top product claims and internal test data for its Rapid Sterility platform at a trade show.
Although there is no independent sales force for Rapid Sterility, the existing sales team has been trained on the platform, and Sterility specialists will provide support during detailed customer discussions.
Rapid Micro Biosystems在第一季度推出了三個Growth Direct系統，擴大了其當前客戶的業務
預計客戶興趣的增加將加速2024年下半年的系統部署。
該公司計劃提高毛利率，並預計到2024年下半年將取得積極業績。
Rapid Sterility平台計劃於2024年中期推出，客戶的興趣正在上升。
通過平衡收入增長、提高利潤率和受監管的運營支出，該公司制定了減少現金消耗的戰略。
擴張計劃包括吸引更多全球前20家公司，擴大客戶群，將無菌注射劑製造等各個細分市場包括在內。
該公司在貿易展上展示了其Rapid Sterility平台的主要產品聲明和內部測試數據。
儘管Rapid Sterility沒有獨立的銷售隊伍，但現有的銷售團隊已經在平台上接受了培訓，Sterility專家將在詳細的客戶討論中提供支持。
More details: Rapid Micro Biosystems IR
更多詳情： 快速微生物系統紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。